Cardiovascular management of Marfan syndrome in the young

Current Treatment Options in Cardiovascular Medicine

Volumn 8, Issue 5, 2006, Pages 396-402

  Sharkey, Angela M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRILLIN; PROPRANOLOL;

AORTA DISEASE; AORTA DISSECTION; AORTA ROOT; AUTOSOMAL DOMINANT DISORDER; BONE DISEASE; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD; CONNECTIVE TISSUE DISEASE; DRUG EFFICACY; EYE DISEASE; GENE MUTATION; GENETIC SCREENING; HUMAN; INCIDENCE; LIFESPAN; LIFESTYLE; MARFAN SYNDROME; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PHENOTYPE; PROPHYLAXIS; REVIEW; SURGICAL TECHNIQUE;

EID: 33749031529     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-006-0044-4     Document Type: Review

References (28)

1. Pyeritz RE: Marfan syndrome and other disorders of fibrillin. In Principles and Practice of Medical Genetics, edn 3. Edited by Rimoin DL, et al. New York: Churchill Livingstone; 1997:1027-1066.
2. Dietz HC, Cutting GR, Pyeritz RE, et al.: Defects in the fibrillin gene cause the Marfan syndrome: linkage evidence and identification of a missense mutation. Nature 1991, 352:337-339.
3. Collod-Beroud G: Marfan database. Nucleic Acids Res 1998, 26:229-233.
4. Murdoch JL, Walker BA, Halpern BL, et al.: Life expectancy and causes of death in the Marfan Syndrome. N Engl J Med 1972, 286:804-808.
5. Shores J, Berger KR, Murphy EA, et al.: Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994, 330:1335-1341.
6. Pyreitz RE: Effectiveness of beta-adrenergic blockade in the Marfan syndrome: experience over 10 years. Am J Med Genet 1989, 32:245.
7. Gray JR, Bridges AB, West PR, et al.: Life expectancy in British Marfan syndrome populations. Clin Genet 1998, 54: 124-128.
8. Silverman DI, Burton KJ, Gray J, et al.: Life expectancy in the Marfan syndrome. Am J Cardiol 1995, 75:157-160.
9. DePaepe A, Deitz HG, Devereux RB, et al.: Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996, 62:417-426.
10. Health supervision for children with Marfan syndrome. American Academy of Pediatrics Committee on Genetics [no authors listed]. Pediatrics 1996, 98:978-982.
11. National Marfan Foundation. Available at http://www.marfan.org/nmf/. Accessed April 2006.
12. Dean JCS: Management of Marfan syndrome. Heart 2002, 88:97-103.
13. Roman MJ, Devereux RB, Kramer-Fox R, et al.: Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989, 64:507-512.
14. Loeys BL, Ghen J, Neptune ER, et al.: A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005, 37:275-281.
15. Pyeritz RE: The Marfan syndrome. Ann Rev Med 2000, 51:481-510.
16. Dietz HG, Pyeritz RE: Marfan syndrome and related disorders. In The Metabolic and Molecular Bases of Inherited Disease, edn 8. Edited by Scriver CR, et al. New York: McGraw-Hill; 2000:5287-5311.
17. Maron BJ, Chaitman BR, Ackerman MJ, et al.: Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004, 109:2807-2816.
18. Maron BJ: Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005, 45:1340-1345.
19. Milewicz DM, Dietz HC, Miller DC: Treatment of aortic disease in patients with Marfan Syndrome. Circulation 2005, 111:e150-e157.
20. Rossi-Foulkes R, Roman MJ, Rosen SE, et al.: Phenotypic features and impact of beta blocker or calcium channel antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999, 83:1364-1368.
21. Yetman AT, Bornemeier RA, McCrindle BW: Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005, 95: 1125-1127.
22. Dietz HG, Loeys B, Carta L, Ramirez F: Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet Part C Semin Med Genet 2005, 139:4-9.
23. Judge DP, Dietz HC: Marfan's syndrome. Lancet 2005, 366:1965-1976.
24. Kim SY, Martin N, Hsia EC, et al.: Management of aortic disease in Marfan syndrome: a decision analysis. Arch Intern Med 2005, 165:749-755.
25. Davies RR, Goldstein LJ, Coady MA, et al.: Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002, 73:17-27; discussion 27-28.
26. Zehr KJ, Matloobi A, Connolly HM, et al.: Surgical management of the aortic root in patients with Marfan syndrome. J Heart Valve Dis 2005, 14:121-128; discussion 128-129.
27. Vricella LA, Williams JA, Ravekes WJ, et al.: Early experience with valve-sparing aortic root replacement in children. Ann Thorac Surg 2005, 80:1622-1626; discussion 1626-1627.
28. Pyeritz RE: The Marfan syndrome in childhood: features, natural history and differential diagnosis. Prog Pediatr Cardiol 1996, 5:151-157.